BioCentury | Sep 19, 2020
Product Development

Hexagon to scale up fungal metabolite discovery for new therapeutic compounds with $47M series A

With a focus on fungal infections and cancer, Hexagon is sourcing secondary metabolites from fungal genomes to develop small molecules against new protein targets.  Hexagon Bio Inc. announced...
BioCentury | Jul 21, 2020
Product Development

Amplyx’s first-in-class antifungal heads for a head-to-head study

Following a positive Phase II readout, Amplyx plans to take lead candidate fosmanogepix into a Phase III head-to-head trial against echinocandins as first-line treatment for invasive Candida infections. Echinocandins are standard of care in the...
BioCentury | Sep 3, 2019
Company News

Sept. 3 Company Quick Takes: Mundipharma-Cidara, Roche-Spark, Vascepa

Mundipharma licenses rights to Cidara’s rezafungin Cidara Therapeutics Inc. (NASDAQ:CDTX) granted Mundipharma International Ltd. (Dublin, Ireland) exclusive rights to develop and commercialize rezafungin outside the U.S. and Japan to treat and prevent invasive fungal infections....
BioCentury | Apr 12, 2019
Emerging Company Profile

Bright Angel: New hope against fungal resistance

Bright Angel is tackling antifungal resistance at its root with inhibitors of Hsp90 and other stress response factors, unlike competitors that are developing compounds against known or new pathways where resistance can still emerge. Resistance...
BioCentury | Apr 20, 2018
Clinical News

Cidara reports Phase II data for IV antifungal rezafungin

Cidara Therapeutics Inc. (NASDAQ:CDTX) reported top-line data from 92 patients with candidemia and/or invasive candidiasis in the modified intent-to-treat (ITT) population of the Phase II STRIVE trial showing that once-weekly 400 mg IV rezafungin (formerly...
BioCentury | Feb 24, 2017
Clinical News

CD101 Topical: Phase II RADIANT data

Top-line data from 89 patients with moderate to severe acute vulvovaginal candidiasis in the modified intent-to-treat (ITT) population of the open-label, U.S. Phase II RADIANT trial showed that CD101 topical gel and ointment led to...
BioCentury | Feb 21, 2017
Clinical News

Cidara discontinues CD101 topical for vulvovaginal candidiasis

Cidara Therapeutics Inc. (NASDAQ:CDTX) plummeted $4.50 (38%) to $7.20 on Tuesday after discontinuing development of CD101 topical to treat vulvovaginal candidiasis. Both gel and ointment formulations of the product led to lower clinical and mycological...
BioCentury | Oct 24, 2016
Clinical News

SCY-078: Additional Phase II data

Additional data from 14 patients with invasive candidiasis who were initially treated with IV echinocandin in an open-label, international Phase II trial showed that there were no reports of mycological failure in patients receiving 750...
BioCentury | Aug 25, 2016
Product R&D

Antifungals in the cloud

With its first, acquired, molecule now in Phase II, Cidara Therapeutics Inc. is turning to its home-grown platform to build its preclinical pipeline. The company is borrowing a strategy from cancer immunotherapy to tackle serious...
BioCentury | Aug 15, 2016
Clinical News

SCY-078: Interim Phase II data

Interim data from 22 evaluable patients with invasive candidiasis who were initially treated with IV echinocandin in an open-label, international Phase II trial showed that oral SCY-078 was well tolerated. Scynexis said the optimal dose...
Items per page:
1 - 10 of 175